vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and GLADSTONE COMMERCIAL CORP (GOOD). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $43.5M, roughly 1.0× GLADSTONE COMMERCIAL CORP). GLADSTONE COMMERCIAL CORP runs the higher net margin — 12.4% vs -19.9%, a 32.3% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 16.3%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 10.3%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Gladstone Commercial Corp is a publicly traded US real estate investment trust focused on acquiring, owning, and operating diversified industrial and commercial properties. It offers long-term net lease agreements to tenants across manufacturing, logistics, healthcare and professional services sectors, mainly serving small to mid-sized business clients.

ABCL vs GOOD — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.0× larger
ABCL
$44.9M
$43.5M
GOOD
Growing faster (revenue YoY)
ABCL
ABCL
+772.1% gap
ABCL
788.4%
16.3%
GOOD
Higher net margin
GOOD
GOOD
32.3% more per $
GOOD
12.4%
-19.9%
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
10.3%
GOOD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
GOOD
GOOD
Revenue
$44.9M
$43.5M
Net Profit
$-8.9M
$5.4M
Gross Margin
Operating Margin
-63.7%
Net Margin
-19.9%
12.4%
Revenue YoY
788.4%
16.3%
Net Profit YoY
73.9%
-25.1%
EPS (diluted)
$-0.03
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
GOOD
GOOD
Q4 25
$44.9M
$43.5M
Q3 25
$9.0M
$40.8M
Q2 25
$17.1M
$39.5M
Q1 25
$4.2M
$37.5M
Q4 24
$5.0M
$37.4M
Q3 24
$6.5M
$39.2M
Q2 24
$7.3M
$37.1M
Q1 24
$10.0M
$35.7M
Net Profit
ABCL
ABCL
GOOD
GOOD
Q4 25
$-8.9M
$5.4M
Q3 25
$-57.1M
$4.1M
Q2 25
$-34.7M
$4.6M
Q1 25
$-45.6M
$5.1M
Q4 24
$7.2M
Q3 24
$-51.1M
$11.7M
Q2 24
$-36.9M
$1.6M
Q1 24
$-40.6M
$3.5M
Operating Margin
ABCL
ABCL
GOOD
GOOD
Q4 25
-63.7%
Q3 25
-851.8%
Q2 25
-290.2%
Q1 25
-1479.6%
Q4 24
Q3 24
-1439.4%
Q2 24
-1276.2%
Q1 24
-551.5%
Net Margin
ABCL
ABCL
GOOD
GOOD
Q4 25
-19.9%
12.4%
Q3 25
-637.8%
10.1%
Q2 25
-203.3%
11.7%
Q1 25
-1077.2%
13.7%
Q4 24
19.2%
Q3 24
-785.4%
29.8%
Q2 24
-504.3%
4.3%
Q1 24
-408.0%
9.9%
EPS (diluted)
ABCL
ABCL
GOOD
GOOD
Q4 25
$-0.03
$0.05
Q3 25
$-0.19
$0.02
Q2 25
$-0.12
$0.03
Q1 25
$-0.15
$0.04
Q4 24
$0.10
Q3 24
$-0.17
$0.20
Q2 24
$-0.13
$-0.04
Q1 24
$-0.14
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
GOOD
GOOD
Cash + ST InvestmentsLiquidity on hand
$128.5M
$10.8M
Total DebtLower is stronger
$843.5M
Stockholders' EquityBook value
$966.9M
$171.8M
Total Assets
$1.4B
$1.2B
Debt / EquityLower = less leverage
4.91×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
GOOD
GOOD
Q4 25
$128.5M
$10.8M
Q3 25
$83.2M
$18.4M
Q2 25
$92.4M
$11.7M
Q1 25
$159.3M
$10.4M
Q4 24
$156.3M
$11.0M
Q3 24
$126.6M
$10.5M
Q2 24
$148.3M
$10.4M
Q1 24
$123.6M
$10.5M
Total Debt
ABCL
ABCL
GOOD
GOOD
Q4 25
$843.5M
Q3 25
$843.3M
Q2 25
$794.4M
Q1 25
$740.7M
Q4 24
$693.4M
Q3 24
$692.6M
Q2 24
$722.5M
Q1 24
$719.4M
Stockholders' Equity
ABCL
ABCL
GOOD
GOOD
Q4 25
$966.9M
$171.8M
Q3 25
$964.0M
$184.8M
Q2 25
$1.0B
$177.2M
Q1 25
$1.0B
$183.2M
Q4 24
$1.1B
$171.2M
Q3 24
$1.1B
$168.9M
Q2 24
$1.1B
$145.7M
Q1 24
$1.1B
$147.3M
Total Assets
ABCL
ABCL
GOOD
GOOD
Q4 25
$1.4B
$1.2B
Q3 25
$1.4B
$1.3B
Q2 25
$1.4B
$1.2B
Q1 25
$1.3B
$1.2B
Q4 24
$1.4B
$1.1B
Q3 24
$1.4B
$1.1B
Q2 24
$1.4B
$1.1B
Q1 24
$1.5B
$1.1B
Debt / Equity
ABCL
ABCL
GOOD
GOOD
Q4 25
4.91×
Q3 25
4.56×
Q2 25
4.48×
Q1 25
4.04×
Q4 24
4.05×
Q3 24
4.10×
Q2 24
4.96×
Q1 24
4.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
GOOD
GOOD
Operating Cash FlowLast quarter
$-34.7M
$88.2M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
16.38×
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
GOOD
GOOD
Q4 25
$-34.7M
$88.2M
Q3 25
$-52.6M
$18.9M
Q2 25
$-32.4M
$35.8M
Q1 25
$-11.6M
$17.7M
Q4 24
$-108.6M
$57.0M
Q3 24
$-28.9M
$5.5M
Q2 24
$-30.0M
$13.6M
Q1 24
$-41.7M
$15.0M
Free Cash Flow
ABCL
ABCL
GOOD
GOOD
Q4 25
$-44.6M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
Q4 24
$-187.0M
Q3 24
$-47.4M
Q2 24
$-50.1M
Q1 24
$-65.8M
FCF Margin
ABCL
ABCL
GOOD
GOOD
Q4 25
-99.4%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
Q4 24
-3702.8%
Q3 24
-728.4%
Q2 24
-683.8%
Q1 24
-661.5%
Capex Intensity
ABCL
ABCL
GOOD
GOOD
Q4 25
21.9%
Q3 25
99.7%
Q2 25
78.2%
Q1 25
251.1%
Q4 24
1552.7%
Q3 24
284.6%
Q2 24
274.6%
Q1 24
242.5%
Cash Conversion
ABCL
ABCL
GOOD
GOOD
Q4 25
16.38×
Q3 25
4.57×
Q2 25
7.74×
Q1 25
3.44×
Q4 24
7.93×
Q3 24
0.47×
Q2 24
8.44×
Q1 24
4.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons